Anti-angiogenic therapies for malignant pleural mesothelioma

Author： Ceresoli Giovanni Luca Zucali Paolo Andrea

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.6, 2012-06, pp. : 833-844

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapies currently in Phase II trials for malignant pleural mesothelioma

By Pinton Giulia Manente Arcangela Gabriella Tavian Daniela Moro Laura Mutti Luciano

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1255-1263

Informa Healthcare

Access to resources Recommend Favorite

Anti-Angiogenic Therapies for Children with Cancer

Current Cancer Drug Targets, Vol. 10, Iss. 8, 2010-12 ,pp. : 879-889

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Angiogenic Approaches to Malignant Gliomas

Current Cancer Drug Targets, Vol. 12, Iss. 3, 2012-01 ,pp. : 279-288

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia

Current Cancer Drug Targets, Vol. 11, Iss. 9, 2011-11 ,pp. : 1025-1029

Bentham Science Publishers

Access to resources Recommend Favorite

Pemetrexed/cisplatin worth it in malignant pleural mesothelioma

Inpharma, Vol. 1, Iss. 1627, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite